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A B S T R A C T
Background
Severe pre-eclampsia can cause significant mortality and morbidity for both mother and child, particularly when it occurs remote from
term, between 24 and 34 weeks’ gestation. The only known cure for this disease is delivery. Some obstetricians advocate early delivery
to ensure that the development of serious maternal complications, such as eclampsia (fits) and kidney failure are prevented. Others
prefer a more expectant approach, delaying delivery in an attempt to reduce the mortality and morbidity for the child that is associated
with being born too early.
Objectives
To evaluate the comparative benefits and risks of a policy of early delivery by induction of labour or by caesarean section, after sufficient
time has elapsed to administer corticosteroids, and allow them to take effect; with a policy of delaying delivery (expectant care) for
women with severe pre-eclampsia between 24 and 34 weeks’ gestation.
Search methods
For this update, we searched Cochrane Pregnancy and Childbirth’s Trials Register, ClinicalTrials.gov, the WHO International Clinical
Trials Registry Platform (ICTRP) on 27 November 2017, and reference lists of retrieved studies.
Selection criteria
Randomised trials comparing the two intervention strategies for women with early onset, severe pre-eclampsia. Trials reported in an
abstract were eligible for inclusion, as were cluster-trial designs. We excluded quasi-randomised trials.
Data collection and analysis
Three review authors independently assessed trials for inclusion and risk of bias, extracted data, and checked them for accuracy. We
assessed the quality of the evidence for specified outcomes using the GRADE approach.
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Main results
We included six trials, with a total of 748 women in this review. All trials included women in whom there was no overriding indication
for immediate delivery in the fetal or maternal interest. Half of the trials were at low risk of bias for methods of randomisation and
allocation concealment; and four trials were at low risk for selective reporting. For most other domains, risk of bias was unclear. There
were insufficient data for reliable conclusions about the comparative effects on most outcomes for the mother. Two studies reported
on maternal deaths; neither study reported any deaths (two studies; 320 women; low-quality evidence). It was uncertain whether
interventionist care reduced eclampsia (risk ratio (RR) 0.98, 95% confidence interval (CI) 0.06 to 15.58; two studies; 359 women) or
pulmonary oedema (RR 0.45, 95% CI 0.07 to 3.00; two studies; 415 women), because the quality of the evidence for these outcomes
was very low. Evidence from two studies suggested little or no clear difference between the interventionist and expectant care groups
for HELLP (haemolysis, elevated liver enzymes, and low platelets) syndrome (RR 1.09, 95% CI 0.62 to 1.91; two studies; 359 women;
low-quality evidence). No study reported on stroke. With the addition of data from two studies for this update, there was now evidence
to suggest that interventionist care probably made little or no difference to the incidence of caesarean section (average RR 1.01, 95%
CI 0.91 to 1.12; six studies; 745 women; Heterogeneity: Tau² = 0.01; I² = 63%).
For the baby, there was insufficient evidence to draw reliable conclusions about the effects on perinatal deaths (RR 1.11, 95%CI 0.62 to
1.99; three studies; 343 women; low-quality evidence). Babies whose mothers had been allocated to the interventionist group had more
intraventricular haemorrhage (RR 1.94, 95% CI 1.15 to 3.29; two studies; 537 women; moderate-quality evidence), more respiratory
distress caused by hyaline membrane disease (RR 2.30, 95% CI 1.39 to 3.81; two studies; 133 women), required more ventilation (RR
1.50, 95% CI 1.11 to 2.02; two studies; 300 women), and were more likely to have a lower gestation at birth (mean difference (MD)
-9.91 days, 95% CI -16.37 to -3.45 days; four studies; 425 women; Heterogeneity: Tau² = 31.74; I² = 76%). However, babies whose
mothers had been allocated to the interventionist group were no more likely to be admitted to neonatal intensive care (average RR 1.19,
95% CI 0.89 to 1.60; three studies; 400 infants; Heterogeneity: Tau² = 0.05; I² = 84%). Babies born to mothers in the interventionist
groups were more likely to have a longer stay in the neonatal intensive care unit (MD 7.38 days, 95% CI -0.45 to 15.20 days; three
studies; 400 women; Heterogeneity: Tau² = 40.93, I² = 85%) and were less likely to be small-for-gestational age (RR 0.38, 95% CI
0.24 to 0.61; three studies; 400 women). There were no clear differences between the two strategies for any other outcomes.
Authors’ conclusions
This review suggested that an expectant approach to the management of women with severe early onset pre-eclampsia may be associated
with decreased morbidity for the baby. However, this evidence was based on data from only six trials. Further large, high-quality trials
are needed to confirm or refute these findings, and establish if this approach is safe for the mother.
P L A I N L A N G U A G E S U M M A R Y
Interventionist versus expectant care for severe pre-eclampsia before term
What is the issue?
Women who develop pre-eclampsia (high blood pressure and protein in the urine) before 34 weeks of pregnancy (early onset) are at
risk of severe complications, and even death. These involve the woman’s liver, kidneys, and clotting system, and cause neurological
disturbances, such as headache, visual disturbances, and fits. If the placenta is involved, this can cause growth restriction or reduced
amniotic fluid, placing the baby at risk.
Why is this important?
The only known cure for pre-eclampsia is delivery of the baby. Being born too early can in itself have problems for the baby, even
with the administration of corticosteroids 24 to 48 hours beforehand, to help mature the lungs. Some hospitals follow a policy of early
delivery, within 24 to 48 hours, called interventionist management, whilst others prefer to delay delivery until it is no longer possible
to safely stabilise the woman’s condition, called expectant management.
What evidence did we find?
We searched for evidence in November 2017 and identified six randomised trials. This review included six trials that randomly assigned
women to a policy of interventionist management or expectant management when presenting with severe pre-eclampsia before 34
weeks of pregnancy. A total of 748 women were included in these six trials. Babies born to women allocated to an interventionist
approach were probably more likely to experience adverse effects such as bleeding in the brain (intraventricular haemorrhage). They
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may also have been more likely to require ventilation, have a longer stay in the neonatal unit, have a lower gestation at birth in days, and
weigh less at birth than those babies born to women allocated to an expectant management approach. There was insufficient evidence
for reliable conclusions about the effects on perinatal deaths. Babies whose mothers had been allocated to the interventionist group
were no more likely to be admitted to neonatal intensive care.
There were no maternal deaths in the two studies that reported this outcome. The evidence was very low-quality for the outcome of fits
or convulsions (eclampsia), or of fluid in the lungs (pulmonary oedema), and so it was uncertain whether interventionist care made any
clear difference to the mothers’ health. Evidence from two studies suggested little or no clear difference between the interventionist and
expectant care groups for a severe form of pre-eclampsia, which affects the liver and blood clotting, called HELLP syndrome, which
stands for haemolysis (breakdown of red blood cells), elevated liver enzymes (a sign of liver damage), and low platelets (platelets help
the blood to clot). None of the studies reported on the incidence of stroke in the mother.With the addition of data from two studies for
this update, there was now evidence to suggest that interventionist care probably made little or no difference to the caesarean section
rate.
What does this mean?
In the absence of an over-riding maternal or fetal indication for immediate delivery, delaymay be more beneficial for the baby. However,
there were insufficient data to enable us to draw reliable conclusions about the comparative effects on most outcomes for the mother,
and hence the maternal safety of an expectant approach.
This evidence was based on data from only six trials. Further large trials with long-term follow-up of the children are needed to confirm
or refute whether expectant care is better than early delivery for women who suffer from severe pre-eclampsia before 34 weeks of
pregnancy.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Interventionist care compared to expectant (delayed delivery) care for severe pre-eclampsia
Patient or population: women with severe pre-eclampsia between 24 and 34 weeks’ gestat ion
Setting: hospital sett ings
Intervention: intervent ionist care
Comparison: expectant (delayed delivery) care
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with expectant
(delayed delivery) care
Risk with Intervention-
ist care
Maternal death Study populat ion not est imable 320
(2 RCTs)
⊕⊕©©
LOW a,b
There were no deaths in
either group
0 per 1000 0 per 1000
(0 to 0)
Eclampsia Study populat ion RR 0.98
(0.06 to 15.58)
359
(2 RCTs)
⊕©©©
VERY LOW c,d
6 per 1000 5 per 1000
(0 to 87)
Stroke (brain damage) - - - - - outcome not reported
HELLP syndrome Study populat ion RR 1.09
(0.62 to 1.91)
359
(2 RCTs)
⊕⊕©©
LOW c,e
111 per 1000 121 per 1000
(69 to 212)
Pulmonary oedema Study populat ion RR 0.45
(0.07 to 3.00)
415
(3 RCTs)
⊕©©©
VERY LOW c,f
10 per 1000 4 per 1000
(1 to 29)
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Perinatal mortality or
perinatal death
Study populat ion RR 1.11
(0.62 to 1.99)
343
(3 RCTs)
⊕⊕©©
LOW e,g
105 per 1000 117 per 1000
(65 to 209)
Intraventricular haem-
orrhage or hypoxic is-
chaemic encephalopa-
thy
Study populat ion RR 1.94
(1.15 to 3.29)
537
(2 RCTs)
⊕⊕⊕©
MODERATE c
66 per 1000 127 per 1000
(75 to 216)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; HELLP syndrome: haemolysis, elevated liver enzymes, and low platelets.
Hospital settings were in USA, South Af rica, Egypt, The Netherlands, Lat in America (Panama, Pennsylvania, Mexico, Venezuela, Guatemala, Peru, Ecuador), and Europe
(Belgium, Cyprus, Czech Republic, Germany, Hungary, Greece, Italy, Netherlands, Poland, Portugal, Saudi Arabia, Slovenia, UK)
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
a Lim itat ions in study design (no blinding; -1)
b No events (-1)
c Lim itat ions in study design (no blinding) for one of the studies (-1)
d Low event rate, small sample size and wide CI crossing the line of no ef fect (-2)
e Wide CI crossing the line of no ef fect (-1)
f Small number of events and wide CI crossing the line of no ef fect (-2)
g Lim itat ions in study design (-1)
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B A C K G R O U N D
Pre-eclampsia is a multisystem disorder that is usually associated
with raised blood pressure and proteinuria, but can also involve the
woman’s liver, kidneys, clotting system, or brain. If the placenta is
involved, this may lead to growth restriction or premature birth.
Pre-eclampsia is a relatively common complication of pregnancy,
and can occur at any time during the second half of pregnancy, or
in the first few weeks after delivery. Prediction models for adverse
maternal outcome have been developed and validated in recent
times, but there is still a paucity of data to guide the clinician on
the timing of delivery to ensure safety of both the mother and
the baby in the long term (von Dadelszen 2011). Pre-eclampsia is
described in more detail in the generic protocol on interventions
for treatment of pre-eclampsia and its consequences (Duley 2009).
Description of the condition
Hypertension in pregnancy is defined as a systolic blood pres-
sure of 140 mmHg or more, a diastolic pressure of 90 mmHg
or more, or both. To be diagnosed with pre-eclampsia, the hy-
pertension has to rise de novo after 20 weeks of pregnancy, com-
bined with proteinuria, defined as more than 300 mg of total
protein in a 24-hour urine collection (Davey 1988). Proteinuria
can also be assessed using a spot urine test, which measures the
protein to creatinine ratio. A protein:creatinine ratio of 30 mg/
mmol correlates with a 24-hour protein excretion of more than
300 mg in 24 hours (Morris 2012). This method of estimating
the amount of protein being excreted has several advantages over
the 24-hour urine collection, and was endorsed by NICE (NICE
2010). However, pre-eclampsia is a multi-system disorder, and the
diagnosis of hypertension and proteinuria is considered to be too
restrictive for clinical practice. Clinicians are all too aware that
the disease can present in several ways, and it is necessary to be
vigilant when assessing women with symptoms and signs that are
strongly associated with the disease. This has led to a widening
of the definition for clinical purposes, to include the following:
de novo hypertension after 20 weeks’ gestation, and new onset
of one of the following: a) proteinuria, as defined above; b) renal
insufficiency (creatinine > 0.09 mmol/L, or oliguria; c) liver dis-
ease (raised transaminases, severe right upper quadrant or epigas-
tric pain, or a combination); d) neurological problems: convul-
sions (eclampsia), hyper-reflexia with clonus (involuntary muscu-
lar contractions), severe headaches, persistent visual disturbances
(scotoma); e) haematological disturbances: thrombocytopenia (re-
duced numbers of platelets), disseminated intravascular coagula-
tion, haemolysis; or f ) fetal growth restriction (Brown 2001).
There is no widely accepted definition of severe pre-eclampsia
(Duley 2009). Nevertheless, the features described above, in com-
bination with the early onset of the disease between 24 and 34
weeks’ gestation, would be considered by most clinicians to rep-
resent severe pre-eclampsia. Therefore, we did not define further
or categorise ’severity’.
Description of the intervention
In clinical practice, some units advocate early delivery, which has
been referred to as ’aggressive management’ (Sibai 1984). In this
review, we prefer the term ’interventionist’. This means delivery
by either induction of labour or caesarean section, after corticos-
teroids have been given to improve fetal lung maturation, which
in practice, is after 24 to 48 hours (Crowley 1996; Roberts 2013).
Others prefer to give corticosteroids, stabilise the woman’s con-
dition and then, if possible, aim to delay delivery. This is usually
known as ’expectant management’ (Derham 1989). The great-
est dilemma in deciding when to deliver, is balancing the risks
to mother and baby when the pregnancy is somewhere between
24 and 34 weeks. Early delivery results in a very premature baby,
which could lead to more neonatal complications, such as respira-
tory distress syndrome sometimes called hyalinemembrane disease
(difficulty in breathing and oxygenation), intraventricular haem-
orrhage (bleeding into the cavities of the brain), and necrotising
enterocolitis (bleeding into the wall of the bowel due to a lack
of oxygen). Conversely, delaying delivery in an attempt to allow
fetal maturation could place the mother in jeopardy, and at risk of
multisystem organ failure as outlined above. It also prolongs the
time that a fetus is in a potentially hostile in utero environment.
This in turn, will continue to adversely affect the growth of the
fetus, and may result in an intrauterine death from severe hypoxia,
or an acute event such as an abruption. Although the precise cut-
offs for gestational age will vary with different settings, before 24
weeks, the child has little chance of survival. After 34 weeks, the
prognosis improves, with nearly 100% survival. Between 24 and
34 weeks, mortality decreases with increasing gestational age, but
below 28 weeks, there is considerable risk of survival with severe
disability. A structured review of observational studies found that
expectant care for severe pre-eclampsia, with a prolongation of the
pregnancy by between one and two weeks, was associated with bet-
ter outcomes for babies and low risks for the mother. There were
fewer neonatal deaths and complications of prematurity (Magee
2009).
How the intervention might work
The review compared the merits of two management strategies for
sever pre-eclampsia distant from term. It endeavoured to discover
if one of the strategies: interventionist management, i.e. early de-
livery, or expectant management, i.e. delaying delivery until there
was a specific maternal or fetal indication to intervene, conferred
an advantage to the baby, mother, or both, without causing un-
due risks of morbidity or mortality to one of them. This means,
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improving the intact survival rates of preterm babies without in-
creasing serious morbidity and mortality for the mother.
Why it is important to do this review
This difficult clinical dilemma occurs relatively frequently in large
units, and currently, decisions are based mainly upon personal
experience rather than good evidence. There is a great need for
reliable data to help inform this decision-making.
Other aspects of care forwomenwith severe pre-eclampsia are dealt
with in other reviews. These include drugs for lowering very high
blood pressure (Duley 2013), prophylactic anticonvulsants (Duley
2010), and plasma volume expansion (Duley 1999b). Prevention
of pre-eclampsia is covered by reviews of calcium supplementation
(Hofmeyr 2014), antiplatelets (Duley 2007), salt intake (Duley
1999a; Duley 2005), and magnesium supplementation (Makrides
2014).
O B J E C T I V E S
To evaluate the comparative benefits and risks of a policy of early
delivery by induction of labour or by caesarean section, after suf-
ficient time has elapsed to administer corticosteroids, and allow
them to take effect; with a policy of delaying delivery (expectant
care) for women with severe pre-eclampsia between 24 and 34
weeks’ gestation.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All adequately randomised trials comparing interventionist (ag-
gressive) with expectant care (delayed delivery) for women with
severe early onset pre-eclampsia. We excluded quasi-random de-
signs, such as alternate numbers or allocation by the day of the
week. Trials reported in an abstract were eligible for inclusion, as
were cluster-trial designs.
Types of participants
Women with severe pre-eclampsia who were up to, and including,
34 weeks’ gestation. Severe pre-eclampsia was defined as:
• high blood pressure (> 140/90 mmHg) on two consecutive
occasions four or more hours apart, plus proteinuria higher than
300 mg/24 hours; or
• severe hypertension (blood pressure at least 160 mmHg
systolic, or 110 mmHg diastolic) alone; or
• hypertension as defined above, plus one or more of the
following criteria:
◦ severe proteinuria (usually at least 3 g (range 2 g to 5
g) protein in 24 hours, or 3+ on dipstick);
◦ reduced urinary volume (less than 500 mL in 24
hours), upper abdominal pain, pulmonary oedema;
◦ neurological disturbances (such as headache, visual
disturbances, and exaggerated tendon reflexes);
◦ impaired liver function tests, high serum creatinine,
low platelets); or
◦ suspected intrauterine growth restriction or reduced
amniotic fluid.
This latter set of criteria reflect the natural history of the disease
and clinical practice when diagnosing severe pre-eclampsia.
Types of interventions
Any comparison of a policy of early elective delivery by induction
of labour or by caesarean section (interventionist management)
with a policy of delayed delivery (expectant management). If cor-
ticosteroids were used in the trial, they should have been used for
both types of care. As the beneficial effects of a course of corticos-
teroids are so important, we excluded any study where corticos-
teroids were only administered to one group but not the other.
Types of outcome measures
Primary outcomes
For the woman
• Death
• Eclampsia (fitting)
• Stroke (brain damage)
• HELLP (haemolysis, elevated liver enzymes, and low
platelets) syndrome
• Pulmonary oedema (fluid in the lungs)
For the baby
• Stillbirth
• Neonatal death
• Intraventricular haemorrhage (bleeding in the brain),
hypoxic ischaemic encephalopathy, or both
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Secondary outcomes
For the woman
• Renal failure (kidney failure)
• Liver failure
• Cardiac arrest
• The need for invasive monitoring, such as central venous
catheterisation (intravenous lines into the great veins around the
heart)
• Caesarean section
• Placental abruption
For the baby
• Low Apgar score at five minutes
• Neonatal seizures
• Hyaline membrane disease sometimes referred to as
Respiratory Distress Syndrome (stiff lungs)
• Pneumothorax (air leaks from the lungs)
• Necrotising enterocolitis (bleeding into the bowel wall)
• Ventilation (any ventilation, duration of ventilation)
• Measures of long-term growth and development, such as
important impairment and cerebral palsy
• Small-for-gestational age
• Gestation at birth
Use of health service resources
• Need for intensive care for the woman
• Need for high-dependency care or observation, or both, for
the woman
• Length of stay in neonatal intensive care
• Admission to neonatal intensive care unit
• Surfactant for the baby
• Ventilation for the baby
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Electronic searches
For this update, we searched Cochrane Pregnancy and Child-
birth’s Trials Register by contacting their Information Specialist
(27 November 2017).
The Register is a database containing over 24,000 reports of con-
trolled trials in the field of pregnancy and childbirth. It represents
over 30 years of searching. For full current search methods used to
populate Pregnancy and Childbirth’s Trials Register, including the
detailed search strategies for CENTRAL, MEDLINE, Embase,
and CINAHL; the list of handsearched journals and conference
proceedings, and the list of journals reviewed via the current aware-
ness service, please follow this link to the editorial information
about the Cochrane Pregnancy and Childbirth in the Cochrane
Library, and select the ‘Specialized Register’ section from the op-
tions on the left side of the screen.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals,
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a spe-
cific Pregnancy and Childbirth review topic (or topics), and is
then added to the Register. The Information Specialist searches the
Register for each review using this topic number rather than key-
words. This results in a more specific search set that has been fully
accounted for in the relevant review sections (Included studies;
Excluded studies; Studies awaiting classification; Ongoing stud-
ies).
In addition, we searched ClinicalTrials.gov and the WHO Inter-
national Clinical Trials Registry Platform ( ICTRP) for unpub-
lished, planned, and ongoing trial reports (27 November 2017)
using the methods detailed in Appendix 1.
Searching other resources
We searched the reference lists of retrieved studies.
We did not apply any language or date restrictions.
Data collection and analysis
For methods used in the previous version of this review, see
Churchill 2013.
For this update, the following methods were used to assess the five
reports that were identified as a result of the updated search.
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Selection of studies
Three review authors independently assessed for inclusion all the
potential studies identified as a result of the search strategy. We
resolved any disagreement through discussion, or if required, we
consulted a fourth review author.
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Data extraction and management
We designed a form to extract data. For eligible studies, three
review authors independently extracted the data, using the agreed
form.We resolved discrepancies through discussion, or if required,
we consulted a fourth review author. We entered data into Review
Manager 5 software (RevMan 2014), and checked for accuracy.
When information regarding any of the above was unclear, we
contacted authors of the original reports to provide further details.
Assessment of risk of bias in included studies
Three review authors independently assessed risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). They resolved
disagreements by discussion, or by involving a fourth assessor.
(1) Random sequence generation (checking for possible
selection bias)
We described the method used to generate the allocation sequence
in sufficient detail to allow an assessment of whether it should
produce comparable groups.
For each included study, we assessed the method as being at:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
For each included study, we described the method used to con-
ceal allocation to interventions prior to assignment, and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as being at:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
For each included study, we described the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if theywere blinded, or if we judged that the
lack of blinding was unlikely to affect results. We assessed blinding
separately for different outcomes or classes of outcomes.
We assessed the methods as being at:
• low, high, or unclear risk of bias for participants;
• low, high, or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
For each included study, we described the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as being
at:
• low, high, or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
For each included study, and for each outcome or class of out-
comes, we described the completeness of data, including attri-
tion and exclusions from the analysis. We stated whether attrition
and exclusions were reported, and the numbers included in the
analysis at each stage (compared with the total randomised par-
ticipants), reasons for attrition or exclusion where reported, and
whether missing data were balanced across groups or were related
to outcomes. Where sufficient information was reported, or could
be supplied by the trial authors, we planned to re-include missing
data in the analyses that we undertook.
We assessed methods as being at:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
For each included study, we described how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as being at:
• low risk of bias (where it was clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review were reported);
• high risk of bias (where not all the study’s prespecified
outcomes were reported; one or more reported primary
outcomes were not prespecified; outcomes of interest were
reported incompletely, and so could not be used; study failed to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
9Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
For each included study, we described any important concerns we
had about other possible sources of bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). With
reference to (1) to (6) above, we had planned to assess the likely
magnitude and direction of the bias and whether we considered it
was likely to have an impact on the findings. In future updates, we
will explore the impact of the level of bias through undertaking
sensitivity analyses (Sensitivity analysis).
Assessment of the quality of the evidence using the
GRADE approach
For this update, we assessed the quality of the evidence using the
GRADE approach, as outlined in the GRADE Handbook, in
order to assess the quality of the body of evidence relating to the
following outcomes for the main comparison, interventionist care
versus expectant (GRADE Handbook).
For the woman
• Death
• Eclampsia (fitting)
• Stroke (brain damage)
• HELLP (haemolysis, elevated liver enzymes and low
platelets) syndrome
• Pulmonary oedema (fluid in the lungs)
For the baby
• Perinatal mortality
• Intraventricular haemorrhage (bleeding in the brain),
hypoxic ischaemic encephalopathy, or both
We used the GRADEpro GDT to import data from Review
Manager 5.3 in order to create ’Summary of findings’ tables
(GRADEpro GDT; RevMan 2014). We produced a summary of
the intervention effect and a measure of quality for each of the
above outcomes, using the GRADE approach. The GRADE ap-
proach uses five considerations (study limitations, consistency of
effect, imprecision, indirectness, and publication bias) to assess the
quality of the body of evidence for each outcome. The evidence
can be downgraded fromhigh quality by one level for serious (or by
two levels for very serious) limitations, depending on assessments
for risk of bias, indirectness of evidence, serious inconsistency, im-
precision of effect estimates, or potential publication bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data
We used the mean difference if outcomes were measured in the
same way between trials. We used the standardised mean differ-
ence to combine trials that measured the same outcome, but used
different methods.
Unit of analysis issues
Cluster-randomised trials
We did not identify any cluster-randomised trials for inclusion. If
we identify cluster-randomised trials in future updates, we will in-
clude them in the analyses along with individually-randomised tri-
als. We will adjust their sample sizes, using the methods described
in the Cochrane Handbook for Systematic Reviews of Interventions,
using an estimate of the intracluster correlation co-efficient (ICC)
derived from the trial (if possible), from a similar trial, or from a
study of a similar population. If we use ICCs from other sources,
we will report this, and conduct sensitivity analyses to investigate
the effect of variation in the ICC. If we identify both cluster-
randomised trials and individually-randomised trials, we plan to
synthesise the relevant information. We will consider it reasonable
to combine the results from both if there is little heterogeneity
between the study designs, and the interaction between the effect
of the intervention and the choice of randomisation unit is con-
sidered to be unlikely.
Wewill also acknowledge heterogeneity in the randomisation unit,
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Cross-over trials
Cross-over trials are not a valid study design for this review.
Dealing with missing data
For included studies, we noted levels of attrition. In future updates,
if more eligible studies are included, we will explore the impact
of including studies with high levels of missing data in the overall
assessment of treatment effect by using sensitivity analyses.
For all outcomes, we carried out analyses, as far as possible, on an
intention-to-treat basis, i.e. we attempted to include all partici-
pants randomised to each group in the analyses. The denominator
for each outcome in each trial was the number randomised minus
any participants whose outcomes were known to be missing.
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Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
Tau², I², and Chi² statistics. We regarded heterogeneity as substan-
tial if I² was greater than 30%, and either Tau² was greater than
zero, or there was a low P value (less than 0.10) in the Chi² test
for heterogeneity. If we identified substantial heterogeneity (above
30%), we had planned to explore it by prespecified subgroup anal-
ysis, assuming we had sufficient data.
Assessment of reporting biases
In future updates, if there are 10 or more studies in the meta-
analysis, we will investigate reporting biases (such as publication
bias) using funnel plots. We will assess funnel plot asymmetry
visually. If asymmetry is suggested by a visual assessment, we will
perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using Review Manager 5 soft-
ware (RevMan 2014). We used fixed-effect meta-analysis to com-
bine data where it was reasonable to assume that studies were esti-
mating the same underlying treatment effect: i.e. where trials were
examining the same intervention, and the trials’ populations and
methods were judged sufficiently similar.
If there was clinical heterogeneity sufficient to expect that the un-
derlying treatment effects differed between trials, or if substan-
tial statistical heterogeneity was detected, we used random-effects
meta-analysis to produce an overall summary if an average treat-
ment effect across trials was considered clinically meaningful. The
random-effects summary was treated as the average of the range of
possible treatment effects, and we had planned to discuss the clini-
cal implications of treatment effects differing between trials. If the
average treatment effect is not clinically meaningful, we will not
combine trials. If we used random-effects analyses, we presented
the results as the average treatment effect with 95% confidence
intervals, and the estimates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
In future updates, if we identify substantial heterogeneity and have
sufficient data, we will investigate it using subgroup and sensitivity
analyses. We will consider whether an overall summary is mean-
ingful, and if it is, use random-effects analysis to produce it.
We plan to carry out the following subgroup analyses based on:
1. gestation at trial entry: 24 to 28 weeks’ gestation; 29 to 34
weeks’ gestation; gestation mixed or unknown;
2. suspected intrauterine growth restriction at trial entry:
suspected intrauterine growth restriction; no suspected
intrauterine growth restriction; mixed or unknown.
Wewill explore the following primary outcomes in subgroup anal-
yses.
For the woman
• Death
• Eclampsia (fitting)
• Stroke (brain damage)
• HELLP syndrome
• Pulmonary oedema
For the baby
• Stillbirth
• Neonatal death
• Intraventricular haemorrhage
We will assess differences between subgroups using interaction
tests available in Review Manager 5.
Sensitivity analysis
In future updates, if we identifymore studies to include in analyses,
we plan to carry out sensitivity analyses to explore the effect of risk
of bias assessed by concealment of allocation, high attrition rates,
or both, with studies at high risk of bias being excluded from the
analyses in order to assess whether this makes any difference to the
overall result.
R E S U L T S
Description of studies
Results of the search
See: Figure 1.
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Figure 1. Study flow diagram
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We assessed four new trial reports and also reassessed one ongoing
study. We included two new trials in five reports (Duvekot 2015;
Vigil-De Gracia 2013).
We included four trials in the previous version of this review
(Mesbah 2003; Odendaal 1990; Sibai 1994; Thornton 2004
(GRIT)).
Included studies
We included six trials with a total of 748 women in this review.
The Thornton 2004 (GRIT) trial contributed 262 participants to
this review, which is just under half of the participants recruited
to this trial, which compared management strategies for women
with a growth restricted fetus. The study was jointly funded by
the UK Medical Research Council (MRC), the European Union
Concerted Action, and the Dutch Princess Beatrix Foundation.
There were no declarations of interest, and it took place from
November 1993 to March 2001. The most recent study was the
largest, with 267 women randomised; it was conducted between
August 2010 and August 2012 (Vigil-De Gracia 2013). This trial
was carried out in Latin America, and was funded by the Marjorie
Milham Research Fund, Pennsylvania Hospital, Perelman School
of Medicine, University of Pennsylvannia. The trial only recruited
women between 28 and 33 weeks’ gestation. Participants below
28 weeks were excluded, because it was felt that the neonatal care
provided was too poor, due to limited resources in some units,
which may have restricted generalisablity. There were no declara-
tions of interest by the researchers. The study by Mesbah and col-
leagues recruited women between January 2001 and May 2002.
The funding sources were not disclosed and there were no state-
ments about declarations of interest. The study was judged to be
at high risk of bias due to missing outcome data (Mesbah 2003).
The oldest of the trials was by Odendaal, and published in 1990
(Odendaal 1990). Recruitment took place between January 1986
and January 1988. The study was carried out in South Africa, and
funded by the South African Medical Research Council. There
were no declarations of interest made by the researchers. The fifth
trial was carried out in the USA (Sibai 1994). The trial recruited
95 women from January 1991 to July 1993. The funding source
was not stated, and there were no declarations of interest. The
sixth trial was conducted in the Netherlands, in 2015, and has
only been reported as a poster. No further details were obtained
from the authors (Duvekot 2015).
Setting
Three trials were multi-centre: one was UK based and involved 69
hospitals in 13 European countries (Thornton 2004 (GRIT)), one
was based in Latin America, and was carried out in eight tertiary
hospitals in Latin America (Vigil-DeGracia 2013), and a third was
based in nine hospitals in the Netherlands (Duvekot 2015). The
other three trials were single-centre trials, based in Egypt (Mesbah
2003), South Africa (Odendaal 1990), and the USA (Sibai 1994).
Participants
One trial included 548 pregnant women with fetal growth
restriction, between 24 and 36 weeks’ gestation, an umbili-
cal artery Doppler waveform recorded and clinical uncertainty
about whether immediate delivery was indicated (Thornton 2004
(GRIT)).We included a subset of women from this trial, whowere
at less than or equal to 34 weeks’ gestation (N = 262), and had
severe pre-eclampsia. Vigil-De Gracia 2013 included 267 women
who had severe pre-eclampsia, and were between 28 and 33 weeks’
gestation. Women with the condition, who were at less that 28
weeks’ gestation were excluded from this trial. Mesbah 2003 in-
cluded 30 women with severe pre-eclampsia between 28 and 33
weeks’ gestation; Odendaal 1990 included 38 women with severe
pre-eclampsia between 28 and 34 weeks’ gestation; and Sibai 1994
included 95 women with severe pre-eclampsia at 28 to 32 weeks’
gestation. In four trials, it was explicitly stated that women with
an immediate indication for delivery in the maternal or fetal in-
terest were excluded (Mesbah 2003; Odendaal 1990; Sibai 1994;
Vigil-De Gracia 2013). In one trial, this exclusion was implicit,
since the trial entry criterion was obstetrician uncertainty about
the benefit of immediate or delayed delivery (Thornton 2004
(GRIT)). One trial included 56 women between 28 and 34 weeks
of gestation with severe pre-eclampsia, with or without HELLP
(haemolysis, elevated liver enzymes and low platelets) syndrome
(Duvekot 2015). The trial stopped early due to poor recruitment.
Interventions
In five trials, women had a 24- to 48-hour period of stabilisation,
during which they were given steroids to accelerate fetal lung ma-
turity, and if necessary, magnesium sulphate to prevent seizures,
and antihypertensives to lower blood pressure. If they continued
to meet the eligibility criteria at the end of this period, they were
then randomised. They were either randomised to the interven-
tionist group, which involved immediate delivery by caesarean sec-
tion or induction, or to the expectant management group, who
were managed with hospitalisation and intensive maternal and fe-
tal monitoring. Earlier delivery in this expectant group was im-
plemented if either the maternal or fetal condition deteriorated,
as determined by prespecified criteria. In one trial, women in the
intervention group were delivered immediately, and the control
group were given temporising management (Duvekot 2015).
Outcomes
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The main outcomes in all studies included maternal, perinatal,
and neonatal morbidity and mortality outcomes. Only one trial
included long-term outcomes; measures of long-term growth and
development at two years (Thornton 2004 (GRIT)).
For further details see Characteristics of included studies.
Excluded studies
We excluded two trials as they did not meet the inclusion criteria
of the review (Gruppo di Studio1998; Langenveld 2011). In both
trials, the women did not have severe pre-eclampsia.
See table of Characteristics of excluded studies.
Risk of bias in included studies
Overall, we judged three trials to be at low risk of bias (Sibai 1994;
Thornton 2004 (GRIT); Vigil-DeGracia 2013), two were unclear
(Duvekot 2015; Odendaal 1990), and one was at high risk of bias
(Mesbah 2003).
See Figure 2 and Figure 3 for summaries of ’Risk of bias’ assess-
ment.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item, presented as
percentages across all included studies
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study
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Allocation
In two studies, the methods used for randomisation and conceal-
ment of allocation were not described (Duvekot 2015; Odendaal
1990); in another, the description of concealment of allocation
was unclear, and we were uncertain if this was adequate (Vigil-De
Gracia 2013), and in the other three trials, the methods of both
randomisation and concealment were adequate (Mesbah 2003;
Sibai 1994; Thornton 2004 (GRIT)).
Blinding
Blinding of participants, personnel, or outcome assessors was not
described in four of the trials (Duvekot 2015; Mesbah 2003;
Odendaal 1990; Sibai 1994). One study was described as open
label and recognised that the outcomes were not concealed (Vigil-
De Gracia 2013). Blinding of outcome assessment for long-term
outcomes, such as Griffiths assessment, was reported in one trial
(Thornton 2004 (GRIT)).
Incomplete outcome data
In two trials, all women appeared to have been accounted for in
the results (Sibai 1994; Vigil-De Gracia 2013). In one trial, indi-
vidual patient data for a subset of women with severe pre-eclamp-
sia were provided by the authors of the original trial, and it was
not possible to tell how complete this dataset was (Thornton 2004
(GRIT)). In another trial, it was not clear, from the results ta-
bles, how many were included in the analyses (Odendaal 1990).
In Duvekot 2015, it stated that analysis was by intention-to-treat,
and numbers randomised appeared to be accounted for in the
analyses, but the trial was stopped early because of low recruit-
ment. In one trial, 41 women were recruited, but 11 (27%) were
judged to be too compromised for expectant management, and
were delivered by caesarean section; and after randomisation, five
patients appear to be missing from the results table 2 (Mesbah
2003).
Selective reporting
All expected outcomes appear to have been reported in four tri-
als (Mesbah 2003; Odendaal 1990; Sibai 1994; Thornton 2004
(GRIT)). In one trial, some of the outcomes reported in the trial
registry record and protocol were not reported, but this was prob-
ably due to the trial stopping early, rather than selective reporting
(Duvekot 2015). In one trial, the trial was registered, however the
planned secondary outcomes were listed only as ’Perinatal com-
plications and maternal complications’ (Vigil-De Gracia 2013).
Other potential sources of bias
In two studies, baseline characteristics were similar between groups
and no other sources of bias were apparent (Odendaal 1990; Sibai
1994). In one study, other bias may have been introduced, as only
a subset of the original randomised sample provided data for anal-
ysis, but this was not clear (Thornton 2004 (GRIT)). In one study,
the severe group was excluded from the study, and no baseline
characteristics were described for this group of patients (Mesbah
2003). In one study, three women in the expectant management
group were excluded from the analyses. Two women refused to
remain in hospital, and one woman received incorrect treatment
due to physician error in Vigil-De Gracia 2013. In one study, the
trial stopped early due to low recruitment (Duvekot 2015).
Effects of interventions
See: Summary of findings for the main comparison
Interventionist care compared to expectant (delayed delivery) care
for severe pre-eclampsia for severe pre-eclampsia between 24 and
34 weeks’ gestation
1. Interventionist care versus expectant (delayed
delivery) care for severe pre-eclampsia
Primary outcomes
Three studies (415 women) reported on primary outcomes of rel-
evance to the woman. Two studies reported on maternal death,
and there were no maternal deaths in either study (0/159 vs 0/
161; effect not estimable; two studies, 320 women; low-quality
evidence; Analysis 1.1). Due to very low-quality evidence from
two studies, it was unclear whether interventionist care reduced
eclampsia (risk ratio (RR) 0.98, 95% confidence interval (CI) 0.06
to 15.58; two studies, 359 women; Analysis 1.2), or pulmonary
oedema (RR 0.45, 95%CI 0.07 to 3.00; two studies, 415 women;
Analysis 1.3). Low-quality evidence from two studies suggested
little or no clear difference between the interventionist and expec-
tant care groups for HELLP syndrome (RR 1.09, 95% CI 0.62 to
1.91; two studies, 359 women; Analysis 1.4). Stroke was not an
outcome reported in any trial.
For the baby, there was insufficient evidence for any reliable con-
clusions about the effects on stillbirth (RR 0.30, 95% CI 0.07
to 1.23; five trials; 692 women, with 700 babies), perinatal death
(RR 1.11, 95% CI 0.62 to 1.99; three studies, 343 infants; low-
quality evidence), or neonatal death after delivery (RR 1.32, 95%
CI 0.80 to 2.19; five trials; 485 babies; Analysis 1.6. More babies
whose mothers had been allocated to the interventionist group
had intraventricular haemorrhage (RR 1.94, 95%CI 1.15 to 3.29;
two trials; 537 women; moderate-quality evidence; Analysis 1.7).
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Secondary outcomes
Women allocated to the interventionist group were no more likely
to have a caesarean section than those allocated to an expectant pol-
icy (random-effects, average RR 1.01, 95% CI 0.91 to 1.12; het-
erogeneity: Tau² = 0.01, I² = 63%; six trials; 745 women; Analysis
1.8). There were no clear differences between the two manage-
ment strategies for renal failure (RR 0.32, 95% CI 0.05 to 1.99;
three trials; 397 women; Analysis 1.9), or placental abruption (RR
0.42, 95%CI 0.18 to 0.96; four trials; 453women; Analysis 1.10).
Liver failure, cardiac arrest, and the need for invasive monitoring
for the woman were not reported in any of the trials.
This review suggested that an interventionist policy of care may
be associated with increased morbidity for the baby. For exam-
ple, those babies whose mothers had been allocated to the inter-
ventionist group had more hyaline membrane disease (RR 2.30,
95% CI 1.39 to 3.81; two trials; 133 women; Analysis 1.11), were
more likely to require ventilation (RR 1.50, 95% CI 1.11 to 2.02;
two trials; 300 women; Analysis 1.12), and had a lower gestation
at birth (random-effects, mean difference (MD) -9.91 days, 95%
CI -16.37 to -3.45 days; heterogeneity: Tau² = 31.74, I² = 76%;
four trials; 425 women; Analysis 1.13). There was no clear differ-
ence between the allocated groups in the risk of developing necro-
tising enterocolitis, (RR 1.79, 95% CI 0.84 to 3.81; four trials;
670 women; Analysis 1.14). Babies whose mothers had been al-
located to the interventionist policy were less likely to be small-
for-gestational age (RR 0.38, 95% CI 0.24 to 0.61; three trials;
400 women; Analysis 1.15). In one trial (262 women), there were
no clear differences between the two management strategies for
low Apgar score at five minutes (Analysis 1.16), neonatal seizures
(Analysis 1.17), and three measures of long-term growth and de-
velopment; cerebral palsy (Analysis 1.18), poor hearing, use of
hearing aid (Analysis 1.19), and impaired vision (Analysis 1.20).
Babies whose mothers had been allocated to the interventionist
groupwere nomore likely to be admitted to neonatal intensive care
than the expectant management group (average RR 1.19, 95% CI
0.89 to 1.60; heterogeneity: Tau² = 0.05; I² = 84%; three trials,
400 women Analysis 1.21), or have a longer stay in the neonatal
intensive care unit (random-effects, MD -7.38 days, 95% CI -
0.45 to 15.20 days; heterogeneity: Tau² = 40.93, I² = 85%; three
trials, 400 women; Analysis 1.22), than those allocated to receive
an expectant policy. Other outcomes on the use of health service
resources were not reported in any of the trials (need for intensive
care for the woman; need for high-dependency care or observation,
or both, for the woman; surfactant for the baby).
D I S C U S S I O N
Timing the delivery of a very premature infant in the presence
of severe pre-eclampsia is a difficult clinical decision. When the
mother’s life is in danger, there is no doubt that delivery is the only
correct course of action. This situation is rare. More frequently,
if the pregnancy is continued, the risks of maternal morbidity or
intrauterine fetal demise have to be constantly balanced against the
hazards of prematurity to the fetus if delivered. Most obstetricians
would probably be cautious, and expedite delivery in favour of
the outcome for the mother, and the guarantee of a live baby at
delivery. What is not clear, is to what level, if at all, this adversely
affects the baby.
Only the GRIT study prespecified fetal assessment parameters as
entry criteria into the trial (Thornton 2004 (GRIT)). The other
studies used fetal assessment to trigger delivery if there was evi-
dence of significant compromise. Therefore, it is not possible to
compare the trials for the condition of the fetuses on trial entry.
However, it is unlikely that there would have been any clinical
differences where this was not formally assessed at trial entry. If
there were signs of imminent fetal demise, then the women would
not have been randomised into the trials. But there is the potential
for unseen bias, and future trials must include a formal assessment
of fetal well-being on trial entry.
Currently, there were insufficient data to justify any of our pre-
specified subgroup analyses. These will be included in future up-
dates of this review, when larger trials become available.
There were insufficient data for reliable conclusions from this re-
view. However, the evidence suggests that short-term morbidity
for the baby may be reduced by a policy of expectant care. This
is perhaps surprising, given that expectant management increases
the length of time a fetus is exposed to severe pre-eclampsia, with
the potential to adversely affect fetal growth and well-being. In
fact, this is often stated as a reason for intervention. The results of
this review suggested this may be otherwise. While the babies in
the expectant management group were smaller, their short-term
outcomes were better. Before this policy can be recommended
in clinical practice, further evidence is required to demonstrate
whether there is truly a short-term benefit for the baby without
any increase in mortality, and if so, that it continues in the longer
term. Reassurance is also needed that there is no increase in mor-
bidity for the mother.
Summary of main results
There was insufficient evidence on stillbirth or death after delivery
to draw reliable conclusions about the effects of either policy for
care.However, there was some evidence from this review to suggest
that a policy of prolonging pregnancy reduced serious morbidity
in the neonatal period of life. Fewer babies had an intraventricular
haemorrhage or hyalinemembrane disease, and therewere reduced
levels of ventilation for those allocated to expectant management.
Babies whose mothers were allocated to expectant care were no
more likely to be admitted to the neonatal intensive care unit, and
when admitted, were more likely to stay there for shorter periods
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of time. There were insufficient data to draw any conclusions
about the comparative effects of these two policies of care on the
mothers’ health. Even taken together, these studies did not have
sufficient sample size to demonstrate small tomoderate differences
in maternal outcome.
Overall completeness and applicability of
evidence
There was insufficient evidence from this review to recommend a
particular management policy for this area of obstetric care. The
numbers of participants in the trials was too small to be able to
demonstrate differences in most significant (primary) outcomes,
and where differences were found, there was a considerable level of
heterogeneity, or the contribution was mainly from one trial. The
same was true for the analysis of the secondary outcome measures.
Quality of the evidence
We judged three of the trials included in the review to be at unclear
risk of both performance and detection bias. It was not possible to
blind personnel and participants to interventions, but most out-
comeswere objective outcomes, andwere unlikely to be affected by
blinding, e.g. death, eclampsia. One study was also judged to be at
risk of attrition bias (Mesbah 2003). The Thornton 2004 (GRIT)
trial was not originally designed to examine severe pre-eclamp-
sia. It looked at interventionist versus expectant management for
babies with growth restriction. A by-product of this study, was
that a subset of women also had severe pre-eclampsia, and it was
these women who we included in the review. Overall, we judged
three trials to have a low risk of bias (Sibai 1994; Thornton 2004
(GRIT); Vigil-De Gracia 2013), two as unclear (Duvekot 2015;
Odendaal 1990), and one at a high risk of bias (Mesbah 2003).
We also assessed the quality of the evidence for seven key maternal
and baby outcomes, using the GRADE approach (see Summary of
findings for the main comparison). For eclampsia and pulmonary
oedema, we judged the evidence to be very low-quality, down-
graded due to concerns relating to limitations in study design and
imprecision, due to small sample sizes, small number of events,
and wide confidence intervals crossing the line of no effect. For
maternal death, HELLP (haemolysis, elevated liver enzymes and
low platelets) syndrome, and perinatal mortality, we judged the
evidence to be low-quality, due again to limitations in study design
and imprecision. We judged the evidence for one outcome, intra-
ventricular haemorrhage or hypoxic ischaemic encephalopathy, to
be of moderate quality, downgraded due to limitations in study
design.
Potential biases in the review process
We took steps to minimise bias, although we are aware that bias
may be present in our review. Two review authors independently
assessed studies for eligibility and extracted the data as necessary.
We resolved discrepancies through discussion, or if required, we
consulted a third review author. Two review authors also indepen-
dently performedGRADEassessments, and resolved discrepancies
though discussion. One of the review authors (J Thornton) was
the Principle Investigator for one of the included trials (Thornton
2004 (GRIT)). To remove the potential for bias, the GRIT trial
data were supplied directly to two other review authors from the
trial statistician. J Thornton had no dealings with the acquisition,
preparation, or analysis of the GRIT trial data in this review.
Agreements and disagreements with other
studies or reviews
There were no other systematic reviews of delivery timing in preg-
nancies complicated by pre-eclampsia before 34 weeks. However,
our findings were consistent with the recommendations of all the
expert guidelines reviewed by Gillon 2014, which all recommend
expectant management before 34 weeks, in the absence of uncon-
trollable hypertension, maternal organ failure, or severe fetal com-
promise.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
These data were insufficient to reach any firm conclusions about
the comparative effects of these alternative strategies for the care of
women with severe, early onset pre-eclampsia, in the absence of an
over-riding maternal or fetal indication for delivery. Nevertheless,
the apparent increase in some measures of neonatal morbidity
associated with interventionist care suggested that early delivery
would need to be justified by a realistic expectation of harm to
the mother if the pregnancy was continued. The current advice
from both the National Insitute for Clinical Excellence and the
World Health Organization seems to reflect this interpretation of
the evidence to date, as both recommend deferring delivery until
there are clear signs of fetal compromise, inability to control the
maternal blood pressure, or evidence of maternal organ failure
(NICE 2010; WHO 2011).
Implications for research
Larger trials are needed to confirm whether the benefits for the
child associatedwith a policy of expectant care are real, andwithout
significant risks, and toprovide reassurance that there is no increase
in risk of morbidity or mortality for the mother.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Duvekot 2015
Methods Multi-centre randomised controlled trial
Setting: 19 hospitals in the Netherlands
Participants 56 women from nine hospitals were randomised.
Inclusion criteria: Women between 28+0 and 34+0 weeks of gestation after admission
for severe pre-eclampsia with or without HELLP syndrome
Interventions Immediate delivery (N = 26): delivery 48 hours after admission
Expectant management (N= 30): described as ’temporising management’
Outcomes Primary outcome: composite major maternal and neonatal morbidity and mortality;
maternal long-term outcome defined as persistent morbidity
Women: median prolongation of labour; maternal death; pulmonary edema; placental
abruption, encephalopathy or eclampsia, ARDS (Acute Respiratory Distress Syndrome),
cerebrovascular incident, liver haematoma or liver rupture, acute fatty liver of pregnancy,
severe renal insufficiency, thromboembolism
Baby: neonatal morbidity; neonatal death; birthweight; long-term neonatal outcome
using Bailey-3 assessment
Notes The trial closed after 24 months because of low recruitment. Power analysis estimated
1130 women needed to rule out an increase in adverse perinatal outcome, with at most
5%
Dates of the study: June 2011 to June 2013
Funding sources: Erasmus Medical Center
Declarations of interest: none mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details on method for sequence genera-
tion in abstract presented at poster session
Allocation concealment (selection bias) Unclear risk Nodetails onmethodof allocation conceal-
ment in abstract presented at poster session
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Nodetails onblinding in abstract presented
at poster session
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Nodetails onblinding in abstract presented
at poster session
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Duvekot 2015 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk States that analysis was by intention-to-
treat and numbers randomised appeared to
be accounted for in analyses
Selective reporting (reporting bias) Unclear risk Difficult to tell, because some of the out-
comes reported in the trial registry record
and protocol were not reported in the ab-
stract, but probably due to the trial stop-
ping early, and so many of the outcomes
may not have been reported, rather than
selectively reported
Other bias Unclear risk The trials was stopped early because of low
recruitment.
Mesbah 2003
Methods Randomisation was generated from a random number sequence table. Blind allocation
was made using consecutively sealed envelopes. Odd numbers = aggressive management,
even numbers = expectant management. Analysis was by ITT. Follow-up was judged to
be 100%
Participants 30 pregnant women with severe PE between 28 and 33 + 6 days gestation. Severe PE was
defined as a BP > 180/120 mmHg on 2 occasions, 30 minutes apart; or a BP between
160 to 180/110 to 120 mmHg on 2 occasions, 6 hrs apart. All participants had > 500
mg of proteinuria on a 24 hr urine collection measure. Exclusions were women who
needed delivery for either a maternal or fetal condition in the 1st 24 hrs
Interventions The group assigned to aggressive management were given steroids, and then allowed
48 hrs to lapse before either an induction of labour was attempted or CS carried out.
Women assigned to expectant management also had steroids, but were then managed
conservatively with bedrest, observations, and nifedipine to control their BP. The indi-
cations for delivery in expectant management were: imminent eclampsia, deteriorating
renal function, spontaneous preterm labour, absent EDF, or a non-reassuring CTG, and
reaching 34 weeks
Outcomes Women: days of hospitalisation, imminent eclampsia, eclampsia, HELLP, CS, imminent
eclampsia and deteriorating renal function
Baby: days gained in utero, gestation at delivery, birthweight, admission to SCBU, SGA,
stillbirth, neonatal death, 5-minute Apgar score
Notes In table 2, the total number in the expectant armwas recorded as 10participants, however,
the detail of the table and percentages use the denominator 15. The total looked as if it
was a typographical error. We are seeking information from the author
Dates of the study: January 2001 and May 2002
Funding sources: none disclosed
Declarations of interest: none disclosed
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Mesbah 2003 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Random sequence generated by going
through random number tables till we ob-
tained 30 pairs of numbers from 01 to 30.
”
Allocation concealment (selection bias) Low risk “Randomly assigned to one of twomanage-
ment groups by withdrawing the next en-
velope in a series of 30 consecutively num-
bered, sealed, opaque envelopes.”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No blinding reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No blinding reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 41 women were recruited, but 11 (27%)
judged too compromised for expectant
management, and were delivered by CS
5 patients from the expectant group ap-
peared to be missing from results table 2 -
no explanation
Selective reporting (reporting bias) Low risk All expected outcomes appear to be re-
ported
Other bias High risk Severe group were excluded from the study,
andnobaseline characteristics described for
this group of patients. 5 patients missing
from results for expectant group and no ex-
planation given in the text
Odendaal 1990
Methods Described as ’randomised’. No further information. Blinding in the assessment of out-
come not mentioned. Analysis - ITT basis. Follow-up - 100%
Participants 38 women with severe PE at 28 to 34 weeks’ gestation. Severe PE defined in 4 ways,
depending on BP, proteinuria, and symptoms. Women were either already admitted
for bedrest and later met criteria, or admitted because of severe PE, and after 48 hrs
stabilisation met entry criteria. 10 primigravidae per group
Exclusions: oral antihypertensives before trial entry. Fetal or maternal complications
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Odendaal 1990 (Continued)
necessitating delivery within 48 hrs (20 women excluded before randomisation for this
reason)
Interventions All eligible women in 48 hrs before trial entry:MgSO4 for 24 hrs. If BP 160/110 mmHg,
or more, 6.25 mg dihydralazine boluses. If steroids not already given, betamethasone 12
mg IM, and again after 24 hrs
Interventionist: delivery by either CS or by induction of labour, depending on obstetric
circumstances. If cervix not favourable, prostaglandin E2 tablets. If still not favourable
after 24 hrs, CS
Expectant: bedrest on high-risk obstetric ward, BP controlled with prazosin, weekly be-
tamethasone. Maternal and fetal condition monitored intensively. Delivery at 34 weeks,
unless indicated earlier
Outcomes Women: CS, abruption
Baby: stillbirth, neonatal death,HMD,NEC, pneumothorax, ventilation, days inNICU
(mean), birthweight (mean), gestation at delivery (mean)
Notes 8 women in the interventionist group and 5 in the expectant group deteriorated while
in hospital on bedrest and were randomised immediately
Dates of the study: the trial recruited from January 1986 to January 1988
Funding sources: South African Medical Research Council
Declarations of interest: none stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 58 women eligible with severe PE; 20 had
to be delivered before randomisation be-
cause of severe maternal complications or
fetal distress
20 were randomised to the aggressive-man-
agement group; 18 were randomised to the
expectant group - not clear from results ta-
bles how many analysed - but presume no
loss to follow-up as not described in the text
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Odendaal 1990 (Continued)
ITT not stated
Selective reporting (reporting bias) Low risk All expected outcomes
reported
Other bias Low risk Groups seemed similar - including 20
women excluded prior to randomisation
(correspondence with author)
Sibai 1994
Methods Randomisation was by computer-generated random number. Concealment of allocation
by consecutively-numbered sealed, opaque, envelopes. Analysis - ITT basis. Follow-up
- 100%
Participants 95 women with severe PE at 28 to 32 weeks’ gestation. Severe PE defined as a persistent
elevation of BP ≥ 160/110 mmHg, proteinuria > 500 mg in 24 hrs, and uric acid > 5
mg/dL.
Exclusions: associated medical conditions, renal failure, diabetes or connective tissue
disorders, associated obstetric complications, multiple pregnancies, preterm labour, fetal
compromise (estimated fetal weight < 5th percentile), platelet count < 100,000/mm³
Interventions All eligible women in 24 hrs before trial entry: betamethasone 12 mg, repeated after
24 hrs, MgSO4 for 24 hrs. If BP 160/110 mmHg or more, hydralazine or nifedipine,
depending on clinician preference
Interventionist: delivery by either CS or by induction of labour, on the basis of their
obstetric condition
Expectant: maternal and fetal monitoring on an antenatal ward. If either the maternal
or fetal condition deteriorated, or they reached 34 weeks’ gestation, delivery using the
most appropriate method
Outcomes Women: eclampsia, gestation at delivery (mean), CS, placental abruption, HELLP syn-
drome, renal failure, pulmonary oedema, postpartum length of stay
Baby: birthweight (mean), admission to NICU, length of stay in NICU, SGA, RDS,
NEC, bronchopulmonary dysplasia, cerebral haemorrhage
Notes Dates of the study: the trial recruited from January 1991 to July 1993
Funding sources: not stated
Declarations of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer-generated random
assignments”
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Sibai 1994 (Continued)
Allocation concealment (selection bias) Low risk “Consecutively numbered, sealed, opaque
envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk 129 women had severe PE, but 32 of these
were ineligible because they met 1 or more
of the exclusion criteria, and 2 refused to
participate - 95 women were randomised
(expectant management N = 49; aggressive
management N = 46)
All women appeared to have been ac-
counted for in the results. Appeared to be
ITT
Selective reporting (reporting bias) Low risk All expected outcomes appeared to have
been reported upon
Other bias Low risk The 2 groups were similar with respect to
clinical and laboratory findings
Thornton 2004 (GRIT)
Methods Multi-centre randomised controlled trial
Setting: 69 hospitals in 13 European countries
Participants 547women (588 babies) recruited, outcomeswere available on 547mothers (587 babies)
Inclusion criteria: pregnant women with fetal compromise between 24 and 36 weeks, an
umbilical artery Doppler waveform recorded, and clinical uncertainty whether immedi-
ate delivery was indicated
Interventions Immediate delivery (N = 273; IPD N = 141): deliver now, within 48 hrs to permit
completion of a steroid course
Delayed delivery (N = 274; IPD N = 121): defer delivery, meaning until delivery could
safely be delayed no longer
Outcomes Infant survival to hospital discharge and the Griffith’s development quotient at 2 years
of age
The trial was for compromised preterm fetus: a subset of women within this trial had
severe PE. IPDwere available for this subset and these were the data which were extracted
and analysed for this review. The outcomes for this subset were as follows
For the woman: CS
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Thornton 2004 (GRIT) (Continued)
For the baby:
• intraventricular haemorrhage, hypoxic ischaemic encephalopathy, or both
• Apgar score at 5 minutes
• neonatal seizures
• NEC
• ventilation
• measures of long-term growth and development (e.g. CP diagnosis, Griffiths
score)
• gestational age at birth
Notes Only a subset of IPD data were included and analysed in this review (women with
hypertension plus either proteinuria or IUGR)
Dates of the study: November 1993 to March 2001
Funding sources: UK Medical Research Council, European Union Concerted Action,
and the Dutch Princess Beatrix Foundation
Declarations of interest: none mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A paper-based number sequence with bal-
anced blocks of 8 to 12 weeks used except
during office hours, when a computer-gen-
erated sequence was used”
Allocation concealment (selection bias) Low risk “An independent programmer organised
allocation, using both randomisation and
minimisation.” “The process was designed
to mask allocation from participating clin-
icians, including those with access to the
central trial office.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind - but most of the out-
comes not likely to be influenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Some blinding of outcome assessment for
long-term outcomes, such as Griffiths as-
sessment: “Assessors were masked to the
child’s group allocations.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk A subset of IPD data was provided of
women with severe PE (N = 262 - hyper-
tension, IUGR, proteinuria, or a combina-
tion). It was not possible to tell how com-
plete this dataset was, as it was provided by
the authors of the original study
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Thornton 2004 (GRIT) (Continued)
Selective reporting (reporting bias) Low risk All expected outcomes appeared to have
been reported upon.
Other bias Unclear risk Unclear. Other bias may have been intro-
duced, as only a subset of the original ran-
domised sample provided data for analysis
Vigil-De Gracia 2013
Methods Randomised controlled trial (open label). 8 tertiary teaching hospitals in Latin America
with experience of managing severe PE. 425 eligible women, 158 declined to participate,
267 randomised
Participants Inclusion criteria: pregnant women between 28 and 33 weeks’ gestation with severe PE,
severe gestational hypertension, and super-imposed PE
Exclusion criteria: pregnant women with HELLP syndrome, renal failure, vaginal bleed-
ing, spontaneous rupture of membranes, placenta praevia, gestational diabetes or dia-
betes mellitus, autoimmune disease, fetal growth restriction, reduced amniotic fluid, and
reversed EDF
Interventions Experimental intervention: delivery between 24 and 72 hrs following the administration
of glucocorticoids for fetal lung maturity. Total number randomised: N = 133
Control or comparison intervention: glucocorticoid administration, then planned expec-
tant management with delivery for maternal or fetal indications, or reaching 34 weeks.
Total number randomised: N = 134 (131 analysed)
Outcomes Primary outcome: perinatal mortality (fetal and neonatal death)
Secondary outcomes: composite neonatal morbidities (RDS, IVH, necrotizing entero-
colitis, neonatal sepsis); neonatal data (birthweight, SGA, Apgar scores at 1 and 5 min-
utes, NICU admission, length of NICU admission stay, sex (female) of baby); caesarean
delivery, pregnancy prolongation, maternal morbidities (placental abruption, pulmonary
edema, the HELLP syndrome, renal insufficiency, eclampsia, disseminated intravascular
coagulation, oliguria), and death
Notes Dates of the study: August 2010 to August 2012
Funding sources: Marjorie Milham Research Fund, Pennsylvania Hospital, Perelman
School of Medicine, University of Pennsylvannia
Declarations of interest: “The authors report no conflict of interest.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly allocated, using computer-gen-
erated codewith variable block size of 4 and
6
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Vigil-De Gracia 2013 (Continued)
Allocation concealment (selection bias) Unclear risk Central allocation for each hospital made
by the principal investigator. Sealed en-
velopes were used, though does not specify
whether they were sequentially numbered
and opaque
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial due to the nature of the
intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk An attempt was made to blind the treat-
ment allocation to the data abstracter - es-
pecially the neonatologist. However, most
outcomes depended on clinical diagnoses
and others on the responses to those diag-
noses
Incomplete outcome data (attrition bias)
All outcomes
Low risk The authors stated that 2 patients did not
complete the study because they refused to
remain in the hospital, and 1 did not re-
ceive the correct treatment due to physician
error. These 3 patients were excluded from
the analysis. They said the data were not
available for these 3 women. All 3 women
were in the expectant management group.
The authors reported that the analysis was
on an ITT basis
Selective reporting (reporting bias) Unclear risk The trial was registered. However, the
planned secondary outcomes were listed
only as “perinatal complications and ma-
ternal complications”
Other bias Unclear risk Baseline characteristics - no differences be-
tween groups. Minimal loss to follow-up.
Two women refused to remain in hospital
and one women received incorrect treat-
ment due to physician error
BP: blood pressure
CP: cerebral palsy
CS: caesarean section
CTG: cardiotocography
EDF: end diastolic flow
HELLP: haemolysis, elevated liver enzymes, and lowered platelets
HMD: hyaline membrane disease
hrs: hours
IM: intramuscular
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IPD: individual patient data
ITT: intention-to-treat
IUGR: intrauterine growth restriction
MgSO4: magnesium sulphate
NEC: necrotising enterocolitis
NICU: neonatal intensive care unit
PE: pre-eclampsia
RDS: respiratory distress syndrome
SCBU: special care baby unit
SGA: small-for-gestational age
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Gruppo di Studio1998 Not women with severe pre-eclampsia
This randomised trial compared routine treatment with calcium channel blockers in mild to moderate
hypertension
Langenveld 2011 Not women with severe pre-eclampsia
Thismulti-centre, randomised trial compared induction of labour versus expectant monitoring for gestation
hypertension or mild pre-eclampsia
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D A T A A N D A N A L Y S E S
Comparison 1. Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal death 2 320 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Eclampsia 2 359 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.06, 15.58]
3 Pulmonary oedema 3 415 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.07, 3.00]
4 HELLP syndrome 2 359 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.62, 1.91]
5 Death of the baby (all stillbirths,
neonatal, and infant deaths)
6 760 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.74, 1.60]
6 Death of the baby (subgrouped
by time of death)
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Stillbirth 5 700 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.07, 1.23]
6.2 Perinatal death 3 343 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.62, 1.99]
6.3 Neonatal death 5 485 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.80, 2.19]
6.4 Death after 28 days 1 38 Risk Ratio (M-H, Fixed, 95% CI) 1.8 [0.18, 18.21]
7 Intraventricular haemorrhage
or hypoxic ischaemic
encephalopathy
2 537 Risk Ratio (M-H, Fixed, 95% CI) 1.94 [1.15, 3.29]
8 Caesarean section 6 745 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.91, 1.12]
9 Renal failure 3 397 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.05, 1.99]
10 Placental abruption 4 453 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.18, 0.96]
11 Hyaline membrane disease 2 133 Risk Ratio (M-H, Fixed, 95% CI) 2.30 [1.39, 3.81]
12 Baby ventilated 2 300 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [1.11, 2.02]
13 Gestation at birth (days) 4 425 Mean Difference (IV, Random, 95% CI) -9.91 [-16.37, -3.45]
14 Necrotising enterocolitis 4 670 Risk Ratio (M-H, Fixed, 95% CI) 1.79 [0.84, 3.81]
15 Small-for-gestational age 3 400 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.24, 0.61]
16 Low Apgar score at five minutes
(< 7 at five minutes)
1 262 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [0.87, 2.50]
17 Neonatal seizures 1 262 Risk Ratio (M-H, Fixed, 95% CI) 2.57 [0.27, 24.43]
18 Measures of long-term growth
& development (cerebral palsy)
1 262 Risk Ratio (M-H, Fixed, 95% CI) 6.01 [0.75, 48.14]
19 Measures of long-term growth
& development (poor hearing,
use of hearing aid)
1 262 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.07, 1.74]
20 Measures of long-term growth
& development (impaired
vision)
1 262 Risk Ratio (M-H, Fixed, 95% CI) 4.29 [0.51, 36.22]
21 Admission to neonatal intensive
care unit
3 400 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.89, 1.60]
22 Length of stay in neonatal
intensive care unit (days)
3 400 Mean Difference (IV, Random, 95% CI) 7.38 [-0.45, 15.20]
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Analysis 1.1. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 1 Maternal death.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 1 Maternal death
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Duvekot 2015 0/26 0/30 Not estimable
Vigil-De Gracia 2013 0/133 0/131 Not estimable
Total (95% CI) 159 161 Not estimable
Total events: 0 (Interventionist), 0 (Expectant)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours intervention Favours expectant
Analysis 1.2. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 2 Eclampsia.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 2 Eclampsia
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sibai 1994 0/46 0/49 Not estimable
Vigil-De Gracia 2013 1/133 1/131 100.0 % 0.98 [ 0.06, 15.58 ]
Total (95% CI) 179 180 100.0 % 0.98 [ 0.06, 15.58 ]
Total events: 1 (Interventionist), 1 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours intervention Favours expectant
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Analysis 1.3. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 3 Pulmonary oedema.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 3 Pulmonary oedema
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Duvekot 2015 0/26 1/30 40.9 % 0.38 [ 0.02, 9.01 ]
Sibai 1994 0/46 0/49 Not estimable
Vigil-De Gracia 2013 1/133 2/131 59.1 % 0.49 [ 0.05, 5.37 ]
Total (95% CI) 205 210 100.0 % 0.45 [ 0.07, 3.00 ]
Total events: 1 (Interventionist), 3 (Expectant)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
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Analysis 1.4. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 4 HELLP syndrome.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 4 HELLP syndrome
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sibai 1994 1/46 2/49 9.6 % 0.53 [ 0.05, 5.68 ]
Vigil-De Gracia 2013 21/133 18/131 90.4 % 1.15 [ 0.64, 2.06 ]
Total (95% CI) 179 180 100.0 % 1.09 [ 0.62, 1.91 ]
Total events: 22 (Interventionist), 20 (Expectant)
Heterogeneity: Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours intervention Favours expectant
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Analysis 1.5. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 5 Death of the baby (all stillbirths, neonatal, and infant deaths).
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 5 Death of the baby (all stillbirths, neonatal, and infant deaths)
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sibai 1994 0/46 0/49 Not estimable
Duvekot 2015 1/29 1/31 2.3 % 1.07 [ 0.07, 16.31 ]
Odendaal 1990 5/20 3/18 7.6 % 1.50 [ 0.42, 5.41 ]
Mesbah 2003 6/15 4/15 9.6 % 1.50 [ 0.53, 4.26 ]
Vigil-De Gracia 2013 13/137 12/138 28.7 % 1.09 [ 0.52, 2.31 ]
Thornton 2004 (GRIT) 22/141 20/121 51.7 % 0.94 [ 0.54, 1.64 ]
Total (95% CI) 388 372 100.0 % 1.08 [ 0.74, 1.60 ]
Total events: 47 (Interventionist), 40 (Expectant)
Heterogeneity: Chi2 = 0.86, df = 4 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 6 Death of the baby (subgrouped by time of death).
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 6 Death of the baby (subgrouped by time of death)
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Stillbirth
Sibai 1994 0/46 0/49 Not estimable
Mesbah 2003 0/15 0/15 Not estimable
Vigil-De Gracia 2013 1/137 1/138 12.5 % 1.01 [ 0.06, 15.94 ]
Odendaal 1990 0/20 1/18 19.8 % 0.30 [ 0.01, 6.97 ]
Thornton 2004 (GRIT) 1/141 5/121 67.7 % 0.17 [ 0.02, 1.45 ]
Subtotal (95% CI) 359 341 100.0 % 0.30 [ 0.07, 1.23 ]
Total events: 2 (Interventionist), 7 (Expectant)
Heterogeneity: Chi2 = 1.00, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.67 (P = 0.095)
2 Perinatal death
Odendaal 1990 1/20 2/18 11.7 % 0.45 [ 0.04, 4.55 ]
Mesbah 2003 6/15 4/15 22.1 % 1.50 [ 0.53, 4.26 ]
Vigil-De Gracia 2013 13/137 12/138 66.2 % 1.09 [ 0.52, 2.31 ]
Subtotal (95% CI) 172 171 100.0 % 1.11 [ 0.62, 1.99 ]
Total events: 20 (Interventionist), 18 (Expectant)
Heterogeneity: Chi2 = 0.91, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
3 Neonatal death
Sibai 1994 0/46 0/49 Not estimable
Duvekot 2015 1/29 1/31 4.4 % 1.07 [ 0.07, 16.31 ]
Odendaal 1990 3/20 1/18 4.7 % 2.70 [ 0.31, 23.69 ]
Mesbah 2003 6/15 4/15 18.0 % 1.50 [ 0.53, 4.26 ]
Thornton 2004 (GRIT) 21/141 15/121 72.8 % 1.20 [ 0.65, 2.23 ]
Subtotal (95% CI) 251 234 100.0 % 1.32 [ 0.80, 2.19 ]
Total events: 31 (Interventionist), 21 (Expectant)
Heterogeneity: Chi2 = 0.59, df = 3 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
4 Death after 28 days
Odendaal 1990 2/20 1/18 100.0 % 1.80 [ 0.18, 18.21 ]
0.1 0.2 0.5 1 2 5 10
Favours intervention Favours expectant
(Continued . . . )
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(. . . Continued)
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 20 18 100.0 % 1.80 [ 0.18, 18.21 ]
Total events: 2 (Interventionist), 1 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Chi2 = 3.92, df = 3 (P = 0.27), I2 =23%
0.1 0.2 0.5 1 2 5 10
Favours intervention Favours expectant
Analysis 1.7. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 7 Intraventricular haemorrhage or hypoxic ischaemic encephalopathy.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 7 Intraventricular haemorrhage or hypoxic ischaemic encephalopathy
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thornton 2004 (GRIT) 34/141 16/121 94.5 % 1.82 [ 1.06, 3.14 ]
Vigil-De Gracia 2013 4/137 1/138 5.5 % 4.03 [ 0.46, 35.59 ]
Total (95% CI) 278 259 100.0 % 1.94 [ 1.15, 3.29 ]
Total events: 38 (Interventionist), 17 (Expectant)
Heterogeneity: Chi2 = 0.48, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 2.48 (P = 0.013)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 8 Caesarean section.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 8 Caesarean section
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Mesbah 2003 11/15 9/15 3.8 % 1.22 [ 0.73, 2.04 ]
Odendaal 1990 14/20 15/18 7.1 % 0.84 [ 0.59, 1.20 ]
Duvekot 2015 21/26 27/30 13.8 % 0.90 [ 0.72, 1.12 ]
Sibai 1994 39/46 36/49 14.9 % 1.15 [ 0.94, 1.42 ]
Vigil-De Gracia 2013 118/133 124/131 30.0 % 0.94 [ 0.87, 1.01 ]
Thornton 2004 (GRIT) 137/141 107/121 30.4 % 1.10 [ 1.02, 1.18 ]
Total (95% CI) 381 364 100.0 % 1.01 [ 0.91, 1.12 ]
Total events: 340 (Interventionist), 318 (Expectant)
Heterogeneity: Tau2 = 0.01; Chi2 = 13.69, df = 5 (P = 0.02); I2 =63%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
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Analysis 1.9. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 9 Renal failure.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 9 Renal failure
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Odendaal 1990 0/20 1/18 34.3 % 0.30 [ 0.01, 6.97 ]
Sibai 1994 0/46 0/49 Not estimable
Vigil-De Gracia 2013 1/133 3/131 65.7 % 0.33 [ 0.03, 3.12 ]
Total (95% CI) 199 198 100.0 % 0.32 [ 0.05, 1.99 ]
Total events: 1 (Interventionist), 4 (Expectant)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 10 Placental abruption.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 10 Placental abruption
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Duvekot 2015 0/26 1/30 7.9 % 0.38 [ 0.02, 9.01 ]
Sibai 1994 2/46 2/49 11.0 % 1.07 [ 0.16, 7.25 ]
Odendaal 1990 3/20 4/18 23.9 % 0.68 [ 0.17, 2.62 ]
Vigil-De Gracia 2013 2/133 10/131 57.2 % 0.20 [ 0.04, 0.88 ]
Total (95% CI) 225 228 100.0 % 0.42 [ 0.18, 0.96 ]
Total events: 7 (Interventionist), 17 (Expectant)
Heterogeneity: Chi2 = 2.35, df = 3 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 2.05 (P = 0.040)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 11 Hyaline membrane disease.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 11 Hyaline membrane disease
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Odendaal 1990 11/20 4/18 28.3 % 2.48 [ 0.96, 6.41 ]
Sibai 1994 23/46 11/49 71.7 % 2.23 [ 1.23, 4.04 ]
Total (95% CI) 66 67 100.0 % 2.30 [ 1.39, 3.81 ]
Total events: 34 (Interventionist), 15 (Expectant)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 3.23 (P = 0.0012)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 12 Baby ventilated.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 12 Baby ventilated
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Odendaal 1990 7/20 2/18 4.7 % 3.15 [ 0.75, 13.25 ]
Thornton 2004 (GRIT) 66/141 40/121 95.3 % 1.42 [ 1.04, 1.93 ]
Total (95% CI) 161 139 100.0 % 1.50 [ 1.11, 2.02 ]
Total events: 73 (Interventionist), 42 (Expectant)
Heterogeneity: Chi2 = 1.15, df = 1 (P = 0.28); I2 =13%
Test for overall effect: Z = 2.62 (P = 0.0089)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 13 Gestation at birth (days).
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 13 Gestation at birth (days)
Study or subgroup Interventionist Expectant
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Odendaal 1990 20 211 (15) 18 223 (13) 20.7 % -12.00 [ -20.90, -3.10 ]
Mesbah 2003 15 213 (12) 15 217 (11) 22.0 % -4.00 [ -12.24, 4.24 ]
Sibai 1994 46 216 (14) 49 233 (11) 28.2 % -17.00 [ -22.08, -11.92 ]
Thornton 2004 (GRIT) 141 217 (17) 121 223 (21) 29.0 % -6.00 [ -10.68, -1.32 ]
Total (95% CI) 222 203 100.0 % -9.91 [ -16.37, -3.45 ]
Heterogeneity: Tau2 = 31.74; Chi2 = 12.30, df = 3 (P = 0.01); I2 =76%
Test for overall effect: Z = 3.01 (P = 0.0026)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 14 Necrotising enterocolitis.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 14 Necrotising enterocolitis
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sibai 1994 5/46 0/49 4.9 % 11.70 [ 0.67, 205.88 ]
Odendaal 1990 3/20 1/18 10.5 % 2.70 [ 0.31, 23.69 ]
Vigil-De Gracia 2013 1/137 2/138 20.0 % 0.50 [ 0.05, 5.49 ]
Thornton 2004 (GRIT) 9/141 6/121 64.7 % 1.29 [ 0.47, 3.51 ]
Total (95% CI) 344 326 100.0 % 1.79 [ 0.84, 3.81 ]
Total events: 18 (Interventionist), 9 (Expectant)
Heterogeneity: Chi2 = 3.28, df = 3 (P = 0.35); I2 =8%
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 15 Small-for-gestational age.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 15 Small-for-gestational age
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mesbah 2003 2/15 9/15 16.8 % 0.22 [ 0.06, 0.86 ]
Sibai 1994 5/46 15/49 27.2 % 0.36 [ 0.14, 0.90 ]
Vigil-De Gracia 2013 13/137 30/138 56.0 % 0.44 [ 0.24, 0.80 ]
Total (95% CI) 198 202 100.0 % 0.38 [ 0.24, 0.61 ]
Total events: 20 (Interventionist), 54 (Expectant)
Heterogeneity: Chi2 = 0.82, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 4.03 (P = 0.000055)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 16 Low Apgar score at five minutes (< 7 at five minutes).
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 16 Low Apgar score at five minutes (< 7 at five minutes)
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thornton 2004 (GRIT) 31/141 18/121 100.0 % 1.48 [ 0.87, 2.50 ]
Total (95% CI) 141 121 100.0 % 1.48 [ 0.87, 2.50 ]
Total events: 31 (Interventionist), 18 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 17 Neonatal seizures.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 17 Neonatal seizures
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thornton 2004 (GRIT) 3/141 1/121 100.0 % 2.57 [ 0.27, 24.43 ]
Total (95% CI) 141 121 100.0 % 2.57 [ 0.27, 24.43 ]
Total events: 3 (Interventionist), 1 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 18 Measures of long-term growth & development (cerebral palsy).
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 18 Measures of long-term growth % development (cerebral palsy)
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thornton 2004 (GRIT) 7/141 1/121 100.0 % 6.01 [ 0.75, 48.14 ]
Total (95% CI) 141 121 100.0 % 6.01 [ 0.75, 48.14 ]
Total events: 7 (Interventionist), 1 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.091)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 19 Measures of long-term growth & development (poor hearing, use of hearing aid).
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 19 Measures of long-term growth % development (poor hearing, use of hearing aid)
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thornton 2004 (GRIT) 2/141 5/121 100.0 % 0.34 [ 0.07, 1.74 ]
Total (95% CI) 141 121 100.0 % 0.34 [ 0.07, 1.74 ]
Total events: 2 (Interventionist), 5 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours intervention Favours expectant
47Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.20. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 20 Measures of long-term growth & development (impaired vision).
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 20 Measures of long-term growth % development (impaired vision)
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thornton 2004 (GRIT) 5/141 1/121 100.0 % 4.29 [ 0.51, 36.22 ]
Total (95% CI) 141 121 100.0 % 4.29 [ 0.51, 36.22 ]
Total events: 5 (Interventionist), 1 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 1.21. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 21 Admission to neonatal intensive care unit.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 21 Admission to neonatal intensive care unit
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Mesbah 2003 15/15 10/15 25.2 % 1.48 [ 1.02, 2.13 ]
Sibai 1994 46/46 37/49 37.0 % 1.32 [ 1.12, 1.55 ]
Vigil-De Gracia 2013 95/137 102/138 37.8 % 0.94 [ 0.81, 1.09 ]
Total (95% CI) 198 202 100.0 % 1.19 [ 0.89, 1.60 ]
Total events: 156 (Interventionist), 149 (Expectant)
Heterogeneity: Tau2 = 0.05; Chi2 = 12.34, df = 2 (P = 0.002); I2 =84%
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 1.22. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 22 Length of stay in neonatal intensive care unit (days).
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 22 Length of stay in neonatal intensive care unit (days)
Study or subgroup Interventionist Expectant
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Sibai 1994 46 36.6 (17.4) 49 20.2 (14) 30.1 % 16.40 [ 10.02, 22.78 ]
Mesbah 2003 15 22.3 (5.8) 15 15.7 (4.5) 34.7 % 6.60 [ 2.89, 10.31 ]
Vigil-De Gracia 2013 137 13.8 (14) 138 13.4 (15) 35.1 % 0.40 [ -3.03, 3.83 ]
Total (95% CI) 198 202 100.0 % 7.38 [ -0.45, 15.20 ]
Heterogeneity: Tau2 = 42.29; Chi2 = 19.91, df = 2 (P = 0.00005); I2 =90%
Test for overall effect: Z = 1.85 (P = 0.065)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Search methods for ICTRP and ClinicalTrials.gov
ICTRP
preeclampsia AND remote AND term
preeclampsia AND expectant
preeclampsia AND “before term”
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ClinicalTrials.gov
Advanced search
Study type: Interventional
Condition: preeclampsia
Other terms: preterm or expectant
WH A T ’ S N E W
Last assessed as up-to-date: 27 November 2017.
Date Event Description
27 November 2017 New search has been performed Search updated and two new trials included. The re-
view now includes six trials with 748 women. A ’Sum-
mary of findings’ table was added for this update
27 November 2017 New citation required but conclusions have not
changed
The overall conclusions have not changed substan-
tially. In this update, there was no evidence of a clear
difference between groups for caesarean section, length
of stay in the neonatal intensive care unit, or admission
to neonatal intensive care unit
H I S T O R Y
Protocol first published: Issue 2, 2001
Review first published: Issue 3, 2002
Date Event Description
10 July 2013 New citation required and conclusions have changed Expectant management may be associated with de-
creased morbidity for the baby
28 February 2013 New search has been performed Search updated. Methods updated.
Three studies identified from updated search (Duvekot
2011a; Thornton 2004 (GRIT); Langenveld 2011).
One study has been included (Thornton 2004 (GRIT))
; one is an ongoing study (Duvekot 2011a); and one
study has been excluded (Langenveld 2011).
One study previously in studies awaiting assessment in
the last update has now been included (Mesbah 2003).
16 February 2010 New search has been performed Review updated with new report added to Characteris-
tics of studies awaiting classification
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(Continued)
1 December 2009 Amended Search updated.One new report added to Studies await-
ing classification (Mesbah 2003a)
15 May 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
DC assessed the new trial for risk of bias, extracted the data, and up-dated the text of the review. MM and HA assessed the new trials
for risk of bias, independently extracted the data, and reviewed the final version of the review. LD assessed the new trials for risk of bias
and reviewed the final version. JGT and KW reviewed the final version of the review.
D E C L A R A T I O N S O F I N T E R E S T
David Churchill: None
Lelia Duley: LD has been awarded an NIHR research grant for a programme of work on care at very preterm birth.
Jim G Thornton: Jim Thornton is an author on one of the included studies (Thornton 2004 (GRIT)). However, he was not involved
in any assessment, data extraction, or data analysis of this trial.
Mahmoud Moussa: None
Hind SM Ali: None
Kate F Walker: None
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research, UK.
2013 update - UK NIHR Programme of centrally-managed pregnancy and childbirth systematic reviews of priority to the NHS and
users of the NHS: 10/4001/02
• UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human
Reproduction-HRP, Switzerland.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In 2013, we updated the methods. We modified the inclusion criteria to define more clearly the criteria for types of participants:
Women with severe pre-eclampsia up to and including 34 weeks’ gestation. Severe pre-eclampsia was defined as:
• high blood pressure, > 140/90 mmHg on two consecutive occasions four or more hours apart, and proteinuria higher than 300
mg/24 hours, or
• severe hypertension (blood pressure at least 160 mmHg systolic, or 110 mmHg diastolic) alone; or
• hypertension as defined above plus one or more of the following criteria:
◦ severe proteinuria (usually at least 3 g (range 2 g to 5 g) protein in 24 hours, or 3+ on dipstick);
◦ reduced urinary volume (less than 500 mL in 24 hours), upper abdominal pain, pulmonary oedema;
◦ neurological disturbances (such as headache, visual disturbances, and exaggerated tendon reflexes);
◦ impaired liver function tests, high serum creatinine, low platelets;
◦ suspected intrauterine growth restriction or reduced amniotic fluid.
This latter set of criteria reflect the natural history of the disease and clinical practice when diagnosing severe pre-eclampsia.
We defined primary and secondary outcomes.
We incorporated a ’Summary of findings’ table into the 2017 update.
In 2017, we added an additional search of ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform ( ICTRP).
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Delivery, Obstetric [adverse effects; methods]; ∗Watchful Waiting; Cesarean Section [statistics & numerical data]; Enterocolitis,
Necrotizing [etiology]; Hyaline Membrane Disease [etiology]; Pre-Eclampsia [∗therapy]; Randomized Controlled Trials as Topic
MeSH check words
Female; Humans; Infant, Newborn; Pregnancy
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